-
Mashup Score: 12
Novartis is looking to build on its radiopharma research machinery. The maker of Lutathera and Pluvicto has expanded its long-standing peptide discovery deal with PeptiDream to bolster their work on peptides for conjugation with radionuclide compounds. The Japanese biotech, which has a long list of drug development partners, will get
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 18
Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. The deal will see Ono acquire all outstanding Deciphera stock at a price of $25.60 per share, representing about a 75% premium over its Friday closing price of $14.65. It’s expected to
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
Other longevity researchers have rebuked the Harvard geneticist. “The selling is a step too far,” said one.
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
The
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning. Hudson also said that the French pharma is not expecting a significant impact from the US legislation targeting Chinese service providers given the
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0JPMorgan CEO Jamie Dimon Gives a Soft Landing Long Odds - 6 day(s) ago
Jamie Dimon says the U.S. consumer is in good shape right now, but a huge fiscal deficit and geopolitical challenges make him cautious about the future. The JPMorgan Chase CEO sits down with WSJ Editor in Chief Emma Tucker. Photo: Adam Falk
Source: www.wsj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 20
Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at boosting the company’s focus on high-impact projects. “We’ve taken out 20% of our molecules that have a lower likelihood to succeed, and we’ve added new ones through partnering,”
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 14Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D - 8 day(s) ago
A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug R&D using artificial intelligence, the group exclusively told Endpoints News. The company, Xaira Therapeutics, is one of this year’s most richly funded new companies, not
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 40UK biotech signs $1bn deal to develop liver disease drugs - 9 day(s) ago
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Source: www.ft.comCategories: General Medicine News, General HCPsTweet
Never ever forget that Novartis loves radiopharma. They are playing a well understood card here. By Ayisha Sharma. https://t.co/QeU7c3uQQ7